Form 4: CEL-SCI Chief Scientific Officer Granted 15,000 Stock Options

CEL-SCI Corporation's Chief Scientific Officer, Eyal Talor, was granted 15,000 stock options with an exercise price of $8.20, vesting over three years.

Summary

• Eyal Talor, Chief Scientific Officer of CEL-SCI Corp (CVM), was granted 15,000 stock options.
• The options have an exercise price of $8.20 per share.
• The options vest in three equal annual installments, commencing one year after the grant date of July 28, 2025.
• The options are set to expire on July 27, 2035.
• Following this transaction, Eyal Talor beneficially owns a total of 81,622 derivative securities.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options is a standard compensation practice that aligns executive incentives with shareholder value, but it does not reflect operational performance or financial results directly. It's a routine insider transaction.

Positives

• The grant of stock options to the Chief Scientific Officer aligns management incentives with long-term shareholder value.
• A three-year vesting schedule encourages sustained commitment and performance from a key executive.

Negatives

• This option grant does not provide immediate cash flow to the company.
• Potential future dilution of existing shares if the options are exercised.

Risks

• Future dilution of existing shares if the granted options are exercised by the reporting person.
• The value of the options is contingent on the company's stock price exceeding the exercise price of $8.20 in the future.

Future Outlook

The grant of stock options with a future vesting schedule indicates an expectation of continued employment and potential future value creation for the company, aligning the Chief Scientific Officer's long-term interests with the company's performance.

Industry Context

Stock option grants are a common form of equity compensation in the biotechnology and pharmaceutical industries, used to attract, retain, and incentivize key scientific and executive talent, especially in companies with long development cycles and high R&D costs like CEL-SCI.

Comparison to Industry Standards

• Granting stock options to key executives like the Chief Scientific Officer is a standard practice in the biotech and pharma sectors, comparable to compensation structures at companies such as Moderna, BioNTech, or Regeneron, which heavily rely on scientific innovation.
• The three-year vesting schedule is typical for executive equity awards, promoting long-term retention and performance alignment, similar to practices observed across the S&P 500.
• The exercise price of $8.20 would typically be set at or above the market price on the grant date, a common approach to ensure options are 'at-the-money' or 'out-of-the-money' at issuance, incentivizing future stock price appreciation.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also potential benefit from incentivized management performance.
• Employees: Reflects standard executive compensation practices, potentially signaling stability in key leadership roles.

Next Steps

• The options will begin vesting in three equal annual installments starting July 28, 2026.
• Eyal Talor may exercise the vested options at any time before the expiration date of July 27, 2035.

Key Dates

Recommendation

This Form 4 filing details a routine grant of stock options to a key executive, which is a standard compensation practice aimed at aligning management incentives with long-term shareholder value. It does not provide new information regarding the company's financial performance, operational results, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell the stock.

Keywords

CEL-SCI Corp, CVM, Stock Options, Insider Transaction, Form 4, Eyal Talor, Chief Scientific Officer, Equity Compensation, Biotechnology, Pharmaceuticals